Trial Profile
Ibritumomab tiuxetan Y-90 + rituximab in patients with relapsed/refractory mantle cell lymphoma: a European MCL Network phase II trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Apr 2014
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Antineoplastics; Rituximab
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 15 Apr 2014 New trial record